Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 32 min ago
Peer-reviewedCC BY 4.0JAMA Network Open

Early Adoption and Diffusion of Oral Semaglutide in US Adults With Obesity

  • Yuqing Lei1,2
  • Huilin Tang1,2,3
  • Xinyao Jian2,4
  • David A. Asch5,6,7,8
  • Yong Chen1,2,4,6,9
9 affiliations
  1. 1Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia
  2. 2The Center for Health AI and Synthesis of Evidence, University of Pennsylvania, Philadelphia
  3. 3Center for Preventive Ophthalmology and Biostatistics, Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  4. 4The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia
  5. 5Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  6. 6Leonard Davis Institute of Health Economics, Philadelphia, Pennsylvania
  7. 7Wharton School, University of Pennsylvania, Philadelphia
  8. 8Division of General Internal Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia
  9. 9Penn Medicine Center for Evidence-based Practice, Philadelphia, Pennsylvania
Open at sourceDOICite

Abstract

This cohort study evaluates early treatment trends of oral semaglutide among adults eligible for obesity management medications following its approval for obesity.

Related

  1. Efficacy and safety of semaglutide versus placebo in adults with overweight or obesity without diabetes: updated meta-analysis of randomized trials
    Rida Wajid, Ravi Kumar, Misbah Muneer +12
    Journal of Diabetes and Metabolic DisordersPeer-reviewedLicence not statedFull textPharmacology & toxicologyPMC
  2. Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders
    Masuomi Tomita, Fumiya Harashima, Naoto Takeda +4
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  3. Linafexor, a Pulsatile FXR Agonist, Augments Low-Dose Semaglutide for Weight Loss in Adults with Obesity, MASH, and Type 2 Diabetes
    Y. Zhang, Y. Chen, S. Huang +18
    medRxivPreprintCC BY-NC-NDFull textEndocrinology & metabolismmedRxiv
  4. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis
    Zehra Khatoon Rasool, Rajvi Shah, Ansharah E Zinnia Batool +8
    Frontiers in endocrinologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMCCrossref
  5. Advances in pharmacologic management of obesity: oral semaglutide for weight management
    Fnu Zainab, Abdul Haseeb Hasan
    Annals of medicine and surgery (2012)Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{lei2026early,
  title = {{Early Adoption and Diffusion of Oral Semaglutide in US Adults With Obesity}},
  author = {Yuqing Lei and Huilin Tang and Xinyao Jian and David A. Asch and Yong Chen},
  journal = {JAMA Network Open},
  year = {2026},
  month = oct,
  doi = {10.1001/jamanetworkopen.2026.37779},
  url = {https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2854937},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Early Adoption and Diffusion of Oral Semaglutide in US Adults With Obesity
AU  - Yuqing Lei
AU  - Huilin Tang
AU  - Xinyao Jian
AU  - David A. Asch
AU  - Yong Chen
PY  - 2026
DA  - 2026/10/07
JO  - JAMA Network Open
DO  - 10.1001/jamanetworkopen.2026.37779
UR  - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2854937
AB  - This cohort study evaluates early treatment trends of oral semaglutide among adults eligible for obesity management medications following its approval for obesity.
SN  - 2574-3805
ER  -